The Central Pharmaceutical Affairs Review Committee of the MFDS, which consulted on AstraZeneca's approval of the COVID-19 vaccine, recommended item approval, subject to the submission of ongoing clinical results. In addition, for vaccinations over 65 years of age, it was gathered that opinions should be made carefully in the matters of approval, and that it is recommended to be discussed later in the Korea Advisory Committee on Immunization Practices.

The Central Pharmaceutical Affairs Review Committee held a meeting at the Osong headquarters of the MFDS on the 4th and made this decision.

According to the MFDS, The Central Pharmaceutical Affairs Review Committee recognizes the need for